Sbir phase i: a novel platform for virus enrichment and isolation
Ended Project Grant Awarded Last action
- Award ID
- 2222991
- Recipient
-
Virolock Technologies LIMITED Liability Company UEI HFDXFEHD3ZY9
- Awarding agency
-
National Science Foundation
- Obligated
- $274,459
Award facts
- Assistance listing
- 47.084 NSF Technology, Innovation, and Partnerships
- Completion date
- Originally
- Place of performance
- State College, PA, USA
Award details come from USAspending.gov.
Description
- Abstract
- The broader/commercial impact of this small business innovation research (sbir) phase i project will be the creation of a virus capture technology that may improve the reliability of diagnostic tools needed to detect viral infection in humans, animals, and plants. The proposed device will be designed to be easy to use, portable, and cost-effective, and could accelerate virus detection, providing superior analytical and clinical performance. Early and accurate diagnosis of infectious diseases is critical to curbing the spread of viral infections, improving health outcomes, and reducing economic losses. This technology is a platform potentially applicable to a wide range of target viruses and could be functional in different scenarios like virus surveillance, identification of emerging viruses, and detection of virus mutations. The proposed project seeks to validate the technical feasibility of this technology for direct virus detection methods such as polymerase chain reaction (PCR), immunoassay, and next generation sequencing (NGS), to improve the virus to host ratio and allow for faster results. The project aims to develop a portable sample processing platform that enables high-efficiency virus trapping and purification from field samples (from cotton swabs or tissue biopsy) without using antibodies. This technology uses carbon nanotube arrays to trap virus particles by size discrimination while segregating host contaminants. This technology could be integrated into standard virus diagnostic protocols to achieve a faster, simpler, and more accurate diagnostics compared to traditional processes for virus sample preparation, such as ultracentrifugation and membrane filtration. Currently available state-of-the-art technologies present limitations in extracting pure virus particles from the host material, especially when the viral content is low, usually leading to false negative results. This award reflects NSF's statutory mission and has been deemed worthy of support through evaluation using the foundation's intellectual merit and broader impacts review criteria.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Amendment | $0 | |
| Amendment | $0 | |
| Amendment | $0 | |
| Original award | $274,459 |
Quick answers
Who received award 2222991?
2222991 was awarded to Virolock Technologies LIMITED Liability Company by National Science Foundation on July 1, 2023.
How much is award 2222991 worth?
$274,459 has been obligated on 2222991.
On GovTribe
See this award's full record
- Every transaction and subaward
- The recipient's other awards and teaming partners
- Similar grant awards
- Ask GovTribe AI about this award